
Lonza is a publicly traded Swiss company listed on the SIX Swiss Exchange under the ticker LONN, meaning no single owner controls it, though major institutional shareholders include BlackRock and Baillie Gifford. Headquartered in Basel, Lonza is one of the world's largest CDMOs, reporting CHF 6.5 billion in FY2025 sales with around 19,900 employees across 30-plus sites on three continents.
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Lonza | Lonza Group Ltd | Wholly owned |
Lonza began in 1897 as an industrial venture in the Valais town of Visp, where a consortium built a hydroelectric-powered electrochemical plant taking advantage of alpine water resources. The name comes from the Lonza river, which flows through Visp and powered the original works.
For most of the twentieth century, Lonza was a diversified chemical company producing basic and specialty chemicals, expanding internationally and eventually listing on the SIX Swiss Exchange in 1999. The headquarters moved from Visp to Basel in 2022, though Visp remains its largest manufacturing site and employs thousands.
The transformation into a life sciences champion accelerated through the 2000s and 2010s. Lonza built a leading position in biologics manufacturing, becoming the partner of choice for pharmaceutical companies outsourcing the production of complex therapeutics. It exited specialty chemicals progressively: the 2019 divestiture of Lonza Specialty Ingredients to private equity for $4.7 billion completed the pivot, and the capsule business was sold in 2025, leaving a pure-play CDMO.
Today the group reports three business platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities, spanning mammalian and microbial biologics, cell and gene therapies, bioconjugates, small molecules, and emerging formats. Its largest recent expansion is the $1.2 billion acquisition of Roche's Vacaville biologics site in California in 2024, and it continues investing in Visp and its global network.
FY2025 results underscored the trajectory: sales of CHF 6.531 billion, CORE EBITDA of CHF 2.064 billion at a 31.6 percent margin, and roughly 19,900 permanent employees, with growth driven by biologics demand including antibody-drug conjugates and high-growth modalities.
What is Lonza Group?
It is a Swiss contract development and manufacturing organization, one of the world's largest, producing biologics, small molecules, and advanced therapies for pharmaceutical and biotech customers.
Is Lonza publicly traded?
Yes. It trades on the SIX Swiss Exchange under LONN as a Swiss Market Index constituent, with a secondary listing on the Singapore Exchange.
Who owns Lonza Group?
Its public shareholders. No single controlling owner exists; major institutional holders include BlackRock and Baillie Gifford.
How much revenue does Lonza make?
FY2025 sales were CHF 6.531 billion, with CORE EBITDA of CHF 2.064 billion at a 31.6 percent margin.
Where is Lonza headquartered?
In Basel, Switzerland, since 2022. Its founding and largest site remains Visp in the canton of Valais.
What are Lonza's business platforms?
Integrated Biologics, Advanced Synthesis, and Specialized Modalities, covering biologics, small molecules, cell and gene therapies, and emerging formats.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Adarx Pharmaceuticals | United States | 2019 | Mass market | United states | All Genders | |
| Amgen | USA | 1980 | Market leader | Global | All-ages | |
| Roche | USA | 1976 | Premium | Global | All-ages | |
| Piramal Pharma | India | 2007 | Global leader | Global | All Genders | |
| Regeneron | USA | 1988 | Premium | United states | All Genders |
Healthcare PharmaceuticalsOwned by ADARx Pharmaceuticals, Inc.
Biotechnology brand of ADARx Pharmaceuticals, the San Diego siRNA company that listed on Nasdaq in September 2026.
Healthcare PharmaceuticalsOwned by Amgen Inc.
Master biotechnology brand of Amgen Inc., the world's largest independent biotech, covering its full portfolio of biologic medicines.
Healthcare PharmaceuticalsOwned by Roche
Genentech is a pioneering American biotechnology company and wholly owned member of the Roche Group, headquartered in South San Francisco, California.
Healthcare PharmaceuticalsOwned by Piramal Pharma Limited
Global contract development and manufacturing organization providing integrated CDMO services across the drug lifecycle for pharmaceutical companies. A division of Piramal Pharma Limited.
Healthcare PharmaceuticalsOwned by Regeneron Pharmaceuticals, Inc.
Biotechnology brand of Regeneron Pharmaceuticals, developer of Eylea, Dupixent, and Libtayo, headquartered in Tarrytown, New York.
Market Positioning: Lonza competes with 5 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by Lonza Group Ltd, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by Adcock Ingram Holdings Limited
South African pharmaceutical brand behind Panado and Myprodol, now privately held by Bidvest and NATCO Pharma.
Adcock Ingram is privately owned, unlike Lonza which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Alfa-Pharm CJSC
Armenia's largest pharmaceutical distributor and pharmacy chain, importing medicines from more than 70 global manufacturers since 1996.
Alfa-Pharm is privately owned, unlike Lonza which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Boehringer Ingelheim
German family-owned pharmaceutical brand behind Jardiance and Spiriva, founded in 1885 and still controlled by the Boehringer family.
Boehringer Ingelheim is privately owned, unlike Lonza which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Herbion Pakistan Private Limited
Pakistani natural healthcare company founded in 1983, exporting 250+ herbal, nutraceutical, and personal care products to more than 40 countries.
Herbion is privately owned, unlike Lonza which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Boehringer Ingelheim
Empagliflozin SGLT2 inhibitor for type 2 diabetes, heart failure, and kidney disease, co-marketed by Boehringer Ingelheim and Eli Lilly since its 2014 launch.
Jardiance is privately owned, unlike Lonza which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by TTAM Research Institute
Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.
23andMe is privately owned, unlike Lonza which is under a publicly traded parent company.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.